The AACAP thanks our sponsors for supporting our 55th Annual Meeting. Your support allows us to share the latest in research and practice techniques to an ever increasing national and international audience at our Annual Meeting.
For more information about sponsorship opportunities, please contact the Development Department at development@aacap.org or 202.966.7300, ext. 130.
Gold Level
Bristol-Myers Squibb Company
Eli Lilly and Company
Shire US Inc.
Bronze Level
McNeil Pediatrics, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc.
Novartis Pharmaceuticals Corporation
International Reception
Eli Lilly and Company
Exhibit Hall Reception
Shire US Inc.
Educational Program Support
The American Academy of Child and Adolescent Psychiatry would like to acknowledge the following companies for their support of the scientific sessions below. These funds were provided in response to an application initiated by the AACAP and awarded to the AACAP solely to support the administrative and management costs associated with hosting these programs. Funds were not used to support travel expenses, honoraria, or any other compensation or reimbursement for the speakers. All AACAP Annual Meeting program content is developed independently by the designated presenters and co-authors. External financial support is applied to AACAP events only after the program content has been established and approved by the Program Committee. The Program Committee operates completely independently and is specifically separated from AACAP fundraising and development activities.
AstraZeneca LP: Educational grant in partial support of Clinical Perspectives 7: Multimodal Integrative Treatment for Youth with Bipolar Disorder (MITY-BD)
Bristol-Myers Squibb Company: Educational grant in partial support of Symposium 7: Bipolar Disorder Outcome-Different Ages, Different Stages and Symposium 22: Psychotropic Induced Weight Gain in Children and Adolescents: A Multidisciplinary Approach
National Institute of Mental Health: Educational grant in partial support of the Research Seminar for Early Investigators
Ortho-McNeil Janssen Scientific Affairs, LLC.: Educational grant in partial support of Institute 7: Practical Pediatric Psychopharmacology
Otsuka America Pharmaceutical, Inc.: Educational grant in partial support of the Speaker Ready Room
Shire Pharmaceuticals Inc.: Educational grant in partial support of Symposium 39: Functional and Adaptive Behavior Outcomes in ADHD: Defining and Understanding the Role of Impairment
Support for Scientific Sessions Relating to Substance Abuse
The American Academy of Child and Adolescent Psychiatry would like to thank the National Institute on Drug Abuse for its support of the scientific sessions below. These funds were provided in response to an application initiated by the AACAP and awarded to the AACAP to support the administrative costs associated with hosting the program, as well as stipends and travel expenses for non-federal employees/non-AACAP member presenters.
National Institute on Drug Abuse: Educational grants in partial support of Workshop 15: Grant Writing Workshop and Mock IRG Panel, Symposium 16: Advances in the Treatment of Adolescents with Marijuana Dependence, Symposium 25: The Opioid Dependent Adolescent/Young Adult: Clinical Characteristics, Effectiveness of a Multicenter Opioid Agonist Treatment Study, and Practice Adoption at a Community Program, and Symposium 27: Effects of Stimulant Treatment of ADHD in Childhood and Adolescence and Subsequent Drug Abuse in Adulthood ADHD
denotes Adobe PDF document.
Click here to download the free Adobe PDF reader.
